|5-((3-氯苯基)氨基)苯并[c][2,6]萘啶-8-甲酸钠|CsnPharm

CAS No.: 1309357-15-0

Silmitasertib sodium salt/西米沙替布（CX-4945）钠盐 Catalog No. CSN17673

Synonyms: CX-4945 sodium salt;Silmitasertib Sodium Salt;Silmitasertib sodium

CX-4945 Sodium is a selective inhibitor of CK2 catalytic subunits with an IC50 value of 1 nmol/L.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Protein kinase CK2 is a tetrameric enzyme with two catalytic subunits and two regulatory subunits that constitutively actives serine/threonine protein kinase as a prototypical non-oncogene. CX-4945 Sodium is a selective inhibitor of CK2 catalytic subunits with an IC50 value of 1 nmol/L. Four-hour exposure to 5 and 10 μmol/L CX-4945 in BT-474 cells and BxPC-3 cells caused rapid dephosphorylation of CK2 phophorylation site, Akt (S129), and both canonical regulatory sites, Akt (T308) and Akt (S473). Treatment of BT-474 cells with 1-10 μmol/L CX-4945 for 24 hours induced a G2/M cell-cycle arrest, while the treatment of BxPC-3 cells led to G1/M arrest. Incubating HUVEC cells with 0.1-10 μmol/L CX-4945 led to rapid dephosphorylation of Akt (S129), Akt (T308) and Akt (S473) at 4 hours. Also in HUVEC cells, reduced phosphorylation at the CK2-phosphorylation sites on PTEN (S370/S380) was also observed after 24-hour exposure to 0.1-10 μmol/L CX-4945. CX-4945 inhibited HUVEC cell proliferation, migration, and tube formation with IC50 values of 5.5, 2, and 4 μmol/L at 72 hours, 24 hours and 18 hours, respectively. Treatment of BT-474 and BxPC-3 cells under hypoxic conditions with 5 μmol/L CX-4945 for 48 hours prevented the downregulation of p53 and pVHL. The activation of HIF-1α transcription in Hela cells under hypoxic versus normoxic conditions was also suppressed by 12.5 and 25 μmol/L CX-4945 48 hours after the treatment. In BT-474 xenograft mice, oral administration of 25 and 75 mg/kg CX-4945 twice a day for 31 days inhibited 88% and 97% tumor growth, respectively. In BxPC-3 mouse model, 75 mg/kg bid oral gavage of CX-4945 for 35 days resulted in 93% tumor growth inhibition^[1].
作用机制CX-4945 Sodium acts as an ATP-competitive inhibitor of both isoforms of CK2 catalytic subunits, CK2α and CK2α’, directly blocking the phosphorylation of Akt at Serine 129 in PI3K/Akt signaling pathway^[1].
参考文献

[1] Siddiqui-Jain A, Drygin D, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.6900 mL
- 13.4499 mL
- 26.8998 mL
- 5 mM
- 0.5380 mL
- 2.6900 mL
- 5.3800 mL
- 10 mM
- 0.2690 mL
- 1.3450 mL
- 2.6900 mL

技术信息

CAS号

1309357-15-0

储存条件

粉末: Keep in dark place,Inert atmosphere,Room temperature

液体: -20°C:3-6 月 -80°C:12月

分子式

C19H11ClN3NaO2

运输

蓝冰

分子量

371.75

别名

CX-4945 sodium salt;Silmitasertib Sodium Salt;Silmitasertib sodium;CX-4945

溶解度

DMSO	74.0 mg/mL (199.1 mM)
Ethanol	Insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Silmitasertib sodium salt/西米沙替布（CX-4945）钠盐 Catalog No. CSN17673

靶点选择性

请登录您的专属账户

确认信息